Skip to main content

Table 7 Outcomes of double-refractory RRMM patients included in the main clinical trials

From: The changing landscape of relapsed and/or refractory multiple myeloma (MM): fundamentals and controversies

Study

Phase

Refractoriness

N

ORR

(%)

≥VGPR/CRR/MRD

(%)

Median PFS

(months)

Median OS

(months)

Median DoR

(months)

Pd - MM-003 [52, 168]

3

V + R

225

28

6/-/-

3.7

11.1

7.0

Pd - MM-010 [13]

3

V + R

547

32.4

7.8/0.5/-

4.2

11.9

-

D - SIRIUS [14]

2

PI + IMiD

30

29.7

-

-

-

-

D - GEN501 + SIRIUS [169]

2

PI + IMiD

148*

30.4

14/5/-

4.0

20.5

8.0

IPd – ICARIA-MM [170]

3

PI + R

111

59

29.7/-/-

11.2

-

-

DPd – APOLLO [53]

3

PI + IMiD

64

-

-

7.7

-

-

DPd – MMY-1001 [68]

1

PI + IMiD

73

57.5

-

-

-

-

DKd – CANDOR [51, 164]

3

-

RR: 99

VR: 100

RR: 79.8

VR: 79.0

RR: -/-/13.1

VR: -/-/7.0

RR: NA

VR: 14.2

-

-

DKd – MMY-1001 [171]

1

PI + IMiD

25

83

-/-/6.9

25.7

NA

1y-OS 75%

-

IKd – IKEMA [50]

3

-

RR: 57

VR: 52

-

RR: 66.7/38.6/24.6

VR: 55.8/28.8/17.3

RR: NA

VR: NA

-

-

EloPd – ELOQUENT-3 [78]

2

PI + R

41

-

-

10.2

-

-

KPd – EMN07 [172]

1/2

V + R

21

71

24/5/-

10.3

-

-

Sd – STORM [65]

2b

PI + IMiD + D

122

26

6.56/1.64/-

3.7

8.6

4.4

Belamaf – DREAMM-2 [94]

2

PI + IMiD + D

97

32

18/7/-

2.8

13.7

11

  1. *Patients from GEN-501 and SIRIUS trials who received daratumumab at 16 mg/kg are presented together. Not all are double refractory, but 87% are refractory to IMiD and PI
  2. Belamaf belantamab mafodotin; CRR complete response rate; D daratumumab; DKd: daratumumab/carfolzimib/dexomethasone; DoR duration of response; DPd; daratumumab/pomalidomide/dexamethasone; EloPd elotuzumab/pomalidomide/dexamethasone; IKd isatuximab/carfilzomib/dexamethasone; IMiD immunomodulatory drug; IPd isatuximab/pomalidomide/dexamethasone; Kd carfilzomib/dexamethasone; KPd carfilzomib/pomalidomide/dexamethasone L lenalidomide; LR lenalidomide-refractory; MRD minimal residual disease; NA not achieved; NR not reached; ORR overall response rate; OS overall survival; Pd omalidomide/dexamethasone; PFS progression-free survival; PI proteasome